{'fraction_non_alphanumeric': 0.03263403263403263, 'fraction_numerical': 0.03787878787878788, 'mean_word_length': 5.3357933579335795, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Group B meningococcal outer membrane protein vaccine promote potent anti-viral effect

This report demonstrates a novel method to explore and evaluate the specific humoral/cellular immune response levels and immunoprotective effects of NMB0315 nucleic acid vaccine, recombinant protein vaccine and nucleic acid vaccine + recombinant protein vaccine in combination with mice, and to further explore the effective immunization method for NMB0315 vaccine. This route provides experimental basis. Nucleic acid vaccines [pcDNA3 1(+) / NMB0315] and recombinant protein vaccines (pET 30a / NMB0315) were prepared in large quantities, and immunologically or separately immunized female BALB/c mice were determined by nucleic acid priming protein boosting method. The specific humoral/cell immune response level, the in vitro bactericidal titer of immune serum, and the immunoprotective effect of the vaccine on mice infected with group B meningococcus were observed. Serum-specific IgG, IgG1, IgG2a and genital lavage fluids induced by NMB0315 nucleic acid vaccine group (pNMB0315 CpG), protein vaccine group (rNMB0315 FA) and combined immunization group (pNMB0315 CpG+rNMB0315 FA). The specific sIgA level reached the peak in the eighth week, and the A450 values were in vitro, and the in vitro bactericidal antibody titers of the nucleic acid vaccine group, the protein vaccine group and the combined immunization group were 1, 64, 1128, respectively. The immune protection rate of experimental mice were 70%, 95% and 80%, respectively. At 2, 4, 6, and 8 weeks, the ratio of IgG2a / IgG1 in the nucleic acid vaccine group, the recombinant protein vaccine group, and the combined immunization vaccine group was less than 1.